Remote-Controlled Drug Delivery Implant Can Improve Chronic Disease Management

A Bluetooth-enabled drug delivery technology could vastly improve chronic disease management in the future, according to a recent paper published in Lab on a Chip.
 
Nanomedicine researchers from Houston Methodist successfully tested their new technology, a nanochannel delivery system (nDS), which they remotely controlled to administer long-term delivery of drugs.
 
Patients with chronic diseases, such as rheumatoid arthritis (RA) and heart disease, often take medications that are administered at specific times of the day and require varying dosages. With strict dosing schedules, there is often a risk of treatment interruption or nonadherence that can affect efficacy and safety.
 
Innovative drug delivery systems are often cited as the future of health care medication management. The flexibility of implantable devices to adapt to a patient’s specific treatment needs could significantly reduce nonadherence. Not only can this technology improve patient care, but it can subsequently lead to decreased health care costs as well, according to the study authors.
 
To adapt, the nDS provides continuous, predetermined dosages that are tailored to each patient. According to the researchers, the implant also delivers the drugs long term, often for many months or even a year before refills are needed.
 
“We see this universal drug implant as part of the future of health care innovation,” corresponding author Alessandro Grattoni, PhD, chair of the department of nanomedicine at Houston Methodist Research Institute, said in a press release. “Some chronic disease drugs have the greatest benefit of delivery during overnight hours when it’s inconvenient for patients to take oral medication.”
 
According to the paper, the battery-powered grape-sized implantable device contains a microchip that relies on wireless communication. The researchers demonstrated the release modulation of 2 chronic disease drugs: enalapril and methotrexate, which are first-line therapies for hypertension and RA, respectively. To allow for adjustable administration, they programmed the microchip for 3 different drug release settings: standard, decreased, and increases. For each setting, a specific voltage was applied to a silicon nanochannel within the implant to control drug release.
 
“By leveraging a low intensity electric field to modify the concentration driven diffusion across a nanofluidic membrane, the rate of drug administration can be increased, decreased, or stopped via Bluetooth remote command,” the researchers wrote in the paper.
 
Additionally, the implant’s continuous drug administration helps avoid abrupt fluctuations, which could affect response and tolerability.
 
The researchers said they hope that the technology could eventually be widely available to health care providers to treat patients remotely via telemedicine. The technology is planned for extreme remote communication testing on the International Space Station in 2020.
 
“Our system could set the foundation for an on-demand delivery platform,” the researchers concluded.  
 
Reference
 
Trani ND, Silvestri A, Bruno G, et al. Remotely controlled nanofluidic implantable platform for tunable drug delivery. Lab on a Chip. 2019. http://dx.doi.org/10.1039/c9lc00394k 
 
 
 
 



Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 


Related Articles

Direct-to-consumer prescription drug advertising increased from $1.3 billion to $6 billion over the past 20 years, particularly for high-cost biologics and cancer immunotherapies.
Doug Long, vice president of Industry Relations at IQVIA, discusses rebate reform surrounding Medicare Part D and Part B in an interview with Specialty Pharmacy Times.
A phase 3 study evaluated the safety and efficacy of oral paclitaxel versus intravenous paclitaxel monotherapy in patients with metastatic breast cancer.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2019
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$